Rein Therapeutics Inc.
RNTX | NASDAQ
$0.79
$0 (-0.57%)
Sep 22, 2026, 11:23 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Net Income | -49.87M | -62.88M | -15.73M | -27.33M | -26.16M | -21.16M |
Depreciation & Amortization | 1K | 63K | 119K | 169K | 121K | 163K |
Stock-Based Compensation | 2.22M | 1.12M | 1.19M | 2.08M | 2.26M | 1.89M |
Other Working Capital | -3.93M | 2.69M | -399K | -90K | 628K | -1.4M |
Other Non-Cash Items | 29.86M | 37M | -4K | -208K | -213K | -95K |
Deferred Income Tax | -712K | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -865K | 2.41M | -5.38M | 420K | 242K | -1.28M |
Operating Cash Flow | -19.36M | -22.29M | -19.81M | -24.87M | -23.75M | -20.48M |
Capital Expenditures | n/a | n/a | n/a | n/a | -157K | -5K |
Cash Acquisitions | n/a | n/a | -96K | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | -21.85M | -73.58M | -10.03M |
Sales Maturities Of Investments | n/a | n/a | 16.25M | 48.31M | 37.75M | 16.24M |
Other Investing Acitivies | n/a | n/a | 42K | n/a | 66K | 208K |
Investing Cash Flow | n/a | n/a | 16.2M | 26.46M | -35.92M | 6.41M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | 387K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 7.17M | 15.79M | n/a | 74K | n/a |
Financial Cash Flow | 9.76M | 17.82M | 15.79M | n/a | 55.66M | 15.8M |
Net Cash Flow | -9.65M | -4.47M | 12.12M | 1.59M | -4.01M | 1.74M |
Free Cash Flow | -19.36M | -22.29M | -19.81M | -24.87M | -23.91M | -20.48M |
Adj. Free Cash Flow | -21.59M | -23.41M | -21M | -26.95M | -26.17M | -22.37M |
Maintenance CapEx | n/a | n/a | n/a | n/a | -121K | -5K |
Growth CapEx | n/a | n/a | n/a | n/a | -36K | n/a |
Owner Earnings | -19.36M | -22.29M | -19.81M | -24.87M | -23.88M | -20.48M |
Add to Watchlist
Select watchlists to add or remove RNTX